Fundraising FoxOmega Funds — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Board seatOtello Stampacchia· per SEC Form D
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
BiotechSan Diego, US
John Hood(Co-Founder, Chief Executive Officer & Executive Chairman)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)Monal Mehta(Director)inMiguel de los Rios(Co-Founder & Chief Scientific Officer)in
Co-investorsFidelity InvestmentsLongitude Capital
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNextech InvestNexTech VenturesOrbiMedPontifax Venture Capital+2 more
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)
Co-investorsAvoro Capital AdvisorsOrbiMedOUP (Osage University Partners)Pontifax Venture CapitalCasdin Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Lexeo Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.